Treatment of human podocytes with the sera from patients with recurrent FSGS led to reduction of SMPDL3b expression and ASM activity in these cells, which were associated with actin cytoskeleton remodeling and apoptosis [132]. Here, SMPDL3B is linked to focal segmental glomerulosclerosis.